Indication

Adenocarcinoma of pancreas

Adenocarcinoma of the pancreas is an aggressive malignant neoplasm arising from the epithelial cells of the exocrine pancreas, predominantly originating in the pancreatic ductal system. Read more about Adenocarcinoma of pancreas

124 drugs 78 manufacturers

Advertisement

Drugs that treat it

Common Adenocarcinoma of pancreas therapies.

Showing 1–9 of 124 drugs

MITOMYCIN

MITOMYCIN - SYSTEMIC·ADENOCARCINOMA OF PANCREAS·+1
ACCORD HEALTHCA

TARCEVA (erlotinib HCl)

ANTINEOPLASTIC - PROTEIN-TYROSINE KINASE INHIBITORS·ADENOCARCINOMA OF PANCREAS·+2
GENENTECH
Filter & compare in the drug finder →Opens the drug finder with Adenocarcinoma of pancreas preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Adenocarcinoma of pancreas.

Adenocarcinoma of the pancreas is an aggressive malignant neoplasm arising from the epithelial cells of the exocrine pancreas, predominantly originating in the pancreatic ductal system.

Primarily affecting older adults, it most commonly develops in the head of the pancreas and is pathologically characterized by an extensive desmoplastic stroma, invasive duct-like structures, and frequent somatic alterations such as KRAS mutations.

Due to a lack of early specific symptoms, patients frequently present at advanced stages with painless obstructive jaundice, unintentional weight loss, epigastric pain radiating to the back, vascular encasement, or distant metastatic disease.

Personalize your experience

Follow Adenocarcinoma of pancreas and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it